Goldfinch is singularly focused on discovering and developing precision therapies for patients with kidney disease.
Chronic kidney disease is a driver of mortality across age, race, and stage of disease progression, affecting over 1 in 9 people worldwide. It has emerged as a global epidemic and growing problem that places an enormous social and economic burden on patients, their families, and society.
Advances in kidney transplantation and dialysis over half a century ago extended life for patients with kidney failure, yet the current standard of care for patients with kidney disease remains inadequate, and there is an urgent need for new treatment options.
Recent breakthroughs in genetics and biology have generated an unparalleled understanding of the biological pathways that drive kidney disease. Goldfinch is uniquely positioned to translate these discoveries into new therapies that target the molecular causes of kidney disease.